Drug Discovery Today
AUGUST 9, 2022
The newly announced agenda for Connect in Pharma focuses on innovation as the foundation of a strong pharmaceutical industry in Europe
Drug Channels
AUGUST 9, 2022
Over the weekend, the U.S. Senate passed a massive overhaul of the Medicare Part D program. If passed into law, these changes will have many unintended consequences , but will not address the warped incentives baked into our current rebate system. This makes it a good time to review the murky, little-seen economics of how commercial plan sponsors and payers access the billions of dollars in manufacturer rebates and fee that are negotiated by their pharmacy benefit managers (PBMs).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Antidote
AUGUST 8, 2022
Medical research is how new treatments and therapies move forward, but challenges surrounding patient recruitment can often lead to delays. Patients often have misconceptions about participating in a clinical trial — and if they are interested, they often aren’t sure where to begin.
Crown Bioscience
AUGUST 12, 2022
In this post, we explore the wide variety of inflammatory bowel disease (IBD) mouse models available to researchers, including their unique characteristics. Understanding important differences between these models is key to selecting the optimal one for your specific research questions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Atomwise Blog
AUGUST 12, 2022
At the American Chemical Society Fall National Meeting & Expo, Women Chemists Committee Past WCC Award Winners in Organic & Medicinal Chemistry session, Atomwise member Stephanie Hare, PhD is an invited speaker. Learn what our Atoms have been working on below and visit Atomwise at ACS Fall 2022 National Meeting for other presentation sessions.
Drug Channels
AUGUST 12, 2022
Today’s guest post comes from Divya Iyer, VP, Strategy and Business Development, Pharma Manufacturer Solutions at GoodRx. Divya highlights new GoodRx research on the out-of-pocket cost gap between brand-name and generic prescriptions. She discusses the challenges that providers face when having real-time discussions with patients about out-of-pocket costs.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
AUGUST 10, 2022
Annual Drug Patent Expirations for LUPKYNIS Lupkynis is a drug marketed by Aurinia and is included in one NDA. There are two patents protecting this drug. This drug has one…. The post New patent for Aurinia drug LUPKYNIS appeared first on DrugPatentWatch - Make Better Decisions.
Atomwise Blog
AUGUST 12, 2022
At the American Chemical Society Fall 2022 National Meeting & Expo, Atomwise members were selected to present their research and work. Learn what our Atoms have been working on below and visit Atomwise at ACS Fall 2022 National Meeting for other presentation sessions.
Pharma Manufacturing
AUGUST 10, 2022
A new biomanufacturing era demands that suppliers and manufacturers partner to efficiently bring new therapies to market
Antidote
AUGUST 12, 2022
Recruiting an adequate number of qualified participants is one of the most important aspects of a successful clinical trial — but it is also considered one of the most difficult. Clinical trial recruitment costs make up a major portion of the expenses that study sponsors incur, and when trials have to be delayed due to a lack of participants, each day of the setback can cost sponsors between $600,000 to $8 million.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
AUGUST 10, 2022
Annual Drug Patent Expirations for EPIDIOLEX Epidiolex is a drug marketed by Gw Res Ltd and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent for Gw Res drug EPIDIOLEX appeared first on DrugPatentWatch - Make Better Decisions.
Atomwise Blog
AUGUST 12, 2022
At the American Chemical Society Spring National Meeting & Expo, Atomwise members were selected to present their research and work. Learn what our Atoms have been working on below and visit Atomwise at ACS Fall 2022 National Meeting for other presentation sessions.
Pharma Manufacturing
AUGUST 10, 2022
Annual report finds steady growth and investment in new tools
Antidote
AUGUST 10, 2022
Across all genders and ethnic groups, cardiovascular disease is the leading cause of death in the United States. It is estimated that 8.8 million adults above age 20 have had a heart attack , and 7.6 million have had a stroke. These events can occur for many reasons, but a lesser-known risk factor is elevated lipoprotein(a) (Lp(a)).
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
AUGUST 8, 2022
Annual Drug Patent Expirations for COMPLERA Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are nine…. The post New patent expiration for Gilead Sciences drug COMPLERA appeared first on DrugPatentWatch - Make Better Decisions.
Broad Institute
AUGUST 11, 2022
Scientists discover new antiviral defense system in bacteria By Leah Eisenstadt August 11, 2022 Breadcrumb Home News Scientists discover new antiviral defense system in bacteria Prokaryotes can detect hallmark viral proteins and trigger cell death through a process seen across all domains of life. By Leah Eisenstadt August 11, 2022 Credit: Max Wilkinson Bacterial STAND ATPase proteins (sensing domains shown in blue) bound to viral terminase (left) or portal (right) proteins (gold).
Pharma Manufacturing
AUGUST 9, 2022
Grit and experience give a promising sector teeth
Eye on FDA
AUGUST 8, 2022
Source: CDC. In February 2020 I published a blog posting – Emerging Pathogens, Communications – that encapsulated my observations and learnings from my years work in the early years of the HIV/AIDS pandemic in the early 1980s. As we sit, possibly, on the cusp of another large scale medical challenge with monkeypox, it seemed like a good idea to revisit the topic.
Drug Patent Watch
AUGUST 8, 2022
Annual Drug Patent Expirations for JULUCA Juluca is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent expiration for Viiv Hlthcare drug JULUCA appeared first on DrugPatentWatch - Make Better Decisions.
The Anticancer Fund
AUGUST 8, 2022
8 August 2022 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.
Drug & Device Law
AUGUST 8, 2022
In our civil society, many non-governmental entities certify various things. We’ve all heard of the Good Housekeeping Seal of Approval , which has been around for over a century. Then there is Consumers Union / Consumer Reports – a magazine that does nothing but rate products, and recommends those it rates particularly highly rated or as providing a particularly good value.
Drug Patent Watch
AUGUST 8, 2022
Annual Drug Patent Expirations for EDURANT Edurant is a drug marketed by Janssen Prods and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent expiration for Janssen Prods drug EDURANT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 8, 2022
Annual Drug Patent Expirations for ODEFSEY Odefsey is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are seven…. The post New patent expiration for Gilead Sciences drug ODEFSEY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 8, 2022
Annual Drug Patent Expirations for SUTAB Sutab is a drug marketed by Braintree Labs and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Braintree Labs drug SUTAB appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 7, 2022
Annual Drug Patent Expirations for IXEMPRA+KIT Ixempra Kit is a drug marketed by R-pharm Us Llc and is included in one NDA. It is available from one supplier. There are…. The post New patent expiration for R-pharm Us drug IXEMPRA KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 6, 2022
Annual Drug Patent Expirations for DUAKLIR+PRESSAIR Duaklir Pressair is a drug marketed by Covis and is included in one NDA. There are five patents protecting this drug. This drug has…. The post New patent expiration for COVIS drug DUAKLIR PRESSAIR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 6, 2022
Annual Drug Patent Expirations for TUDORZA+PRESSAIR Tudorza Pressair is a drug marketed by Covis and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent expiration for COVIS drug TUDORZA PRESSAIR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 8, 2022
IXEMPRA KIT (ixabepilone) R-pharm us llc Patent: RE41393 Expiration: Aug 8, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…. The post Drug Patent Expirations for the Week of August 7, 2022 appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 10, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Austria. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Austria? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 9, 2022
This chart shows the companies which have received the most New Product exclusivities in the past five years. New Product Development is one of the categories for which the FDA…. The post Pharmaceutical companies with the most ‘New Product Exclusivity’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 12, 2022
This chart shows the pharmaceutical companies with the most patents in Morocco. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Morocco? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 8, 2022
This chart shows the patent expirations for suspension dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Suspension dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 7, 2022
Pharmaceutical drug patents enable branded drug companies to prevent market entry by competitors until the patents expire. The term of drug patents varies. The basic term for a patent is…. The post Future drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 6, 2022
This chart shows the pharmaceutical companies with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
100 
Let's personalize your content